By Counterforce Health Team in Oxervate (cenegermin) —

How to Get Oxervate (cenegermin) Covered by Humana in Pennsylvania: Appeals Guide and Medical Necessity Templates

Quick Answer: Getting Oxervate Covered by Humana in Pennsylvania

Oxervate (cenegermin) requires prior authorization from Humana for stage 2-3 neurotrophic keratitis. The fastest path: your ophthalmologist submits a medical necessity letter documenting failed conventional treatments (lubricants, bandage lenses) and confirmed corneal sensation loss. If denied, you have 65 days to appeal. For Humana Medicare plans, use federal appeals; for commercial plans, Pennsylvania's new external review program offers a 50% overturn rate. Start today: Request your complete eye chart and treatment history from your ophthalmologist to support the prior authorization.

Table of Contents

Set Your Goal: Understanding Oxervate Approval Requirements

Oxervate (cenegermin) is a high-cost specialty eye drop—an 8-week course commonly costs in the low six figures—used specifically for stage 2 or 3 neurotrophic keratitis. Your partnership with your ophthalmologist is crucial because Humana requires detailed medical necessity documentation before approving this recombinant human nerve growth factor treatment.

Coverage at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required for all Humana plans Humana PA Portal
Diagnosis Documentation Stage 2/3 neurotrophic keratitis with ICD-10 codes Your ophthalmologist's chart notes
Failed Prior Treatments Documented trials of lubricants, bandage lenses Treatment history in medical records
Corneal Sensation Testing Objective measurement showing nerve damage Cochet-Bonnet or cotton wisp test results
Formulary Status Typically non-formulary or restricted access Humana Formulary

The key to approval is demonstrating that conventional treatments have failed and that your corneal nerve damage meets the specific criteria for stage 2 (persistent epithelial defect >2mm) or stage 3 (stromal ulceration with potential perforation).

Visit Preparation: Gathering Your Medical History

Before your ophthalmology appointment, compile a comprehensive timeline that strengthens your case for Oxervate approval.

Essential Information to Gather:

  • Symptom timeline: When did you first notice vision problems, eye discomfort, or corneal issues? Document any triggering events (surgery, infection, trauma).
  • Treatment history: List every eye drop, ointment, or procedure you've tried, including dates and outcomes. This is critical—payers want proof that standard treatments failed.
  • Side effects and intolerances: Note any adverse reactions to previous treatments, as this supports the need for alternatives.
  • Functional impact: Describe how your condition affects daily activities, work, or quality of life.
Tip: Create a simple timeline document with three columns: Date, Treatment/Event, and Outcome. This helps your doctor quickly understand your treatment journey.

Questions to Ask Yourself Before the Visit:

  • Have I tried preservative-free artificial tears for at least 2-4 weeks?
  • Did I use therapeutic bandage contact lenses?
  • Were topical antibiotics prescribed to prevent infection?
  • Have I had any surgical interventions like tarsorrhaphy or amniotic membrane placement?

Building Your Evidence Kit

Your ophthalmologist needs specific documentation to craft a compelling prior authorization request. Request these items from your eye care team:

Clinical Documentation Checklist:

  • Corneal sensation test results (Cochet-Bonnet esthesiometer or cotton wisp measurements)
  • Slit-lamp examination findings with fluorescein staining photos if available
  • Staging documentation using accepted criteria (Mackie classification showing stage 2 or 3)
  • Previous treatment records from all providers who've managed your eye condition
  • Relevant imaging (anterior segment OCT, corneal topography, or in vivo confocal microscopy)
  • Laboratory results if infection or systemic disease contributed to your condition

Published Guidelines and References: Your doctor should reference established treatment guidelines. The FDA labeling for Oxervate specifies its use for neurotrophic keratitis, and ophthalmology societies have published management protocols that support its use when conventional treatments fail.

Medical Necessity Letter Structure

A well-structured medical necessity letter is your strongest tool for Humana approval. Here's the framework your ophthalmologist should follow:

Template Structure:

Patient: [Name, DOB, Humana Member ID]
Diagnosis: Neurotrophic Keratitis, Stage [2/3] - ICD-10: H16.23

CLINICAL RATIONALE:
1. Confirmed diagnosis with objective findings:
   - Corneal sensation testing: [specific results]
   - Persistent epithelial defect size: [measurements]
   - Duration of condition: [timeline]

2. Failed conventional treatments:
   - Preservative-free lubricants: [dates, outcomes]
   - Therapeutic bandage contact lens: [trial period, results]
   - [Other treatments tried]

3. Medical necessity for Oxervate:
   - Risk of corneal perforation without treatment
   - No suitable formulary alternatives
   - FDA-approved indication match

SUPPORTING LITERATURE:
[Citations to peer-reviewed studies, FDA labeling, specialty guidelines]

REQUEST: Prior authorization approval for Oxervate 0.002% 
ophthalmic solution, 1 drop to affected eye 6 times daily for 8 weeks.

Counterforce Health helps patients and clinicians create evidence-backed appeals by analyzing denial letters and crafting targeted rebuttals aligned with payer policies. Their platform identifies the specific denial basis and pulls appropriate clinical citations to strengthen medical necessity arguments.

Supporting Your Doctor's Peer-to-Peer Review

If Humana requests a peer-to-peer review, your availability and preparation can make the difference between approval and denial.

How to Support Your Doctor:

  1. Offer flexible scheduling: Peer-to-peer calls often happen with short notice. Let your doctor know your preferred communication method for updates.
  2. Provide a concise case summary: Write a one-page overview of your condition, treatments tried, and current symptoms. Include specific dates and outcomes.
  3. Gather additional evidence: If new symptoms develop or you have recent test results, share them immediately.

Key Talking Points for Your Doctor:

  • Emphasize the progressive nature of neurotrophic keratitis without treatment
  • Reference specific failed treatments with dates and documented outcomes
  • Cite published literature supporting Oxervate use in your clinical scenario
  • Discuss risks of delay, including potential corneal perforation

After Your Appointment: Documentation and Follow-up

What to Save:

  • Copy of the prior authorization submission
  • All supporting clinical documents
  • Confirmation numbers or submission receipts
  • Your doctor's contact information for the case

Portal Communication: Use your patient portal to:

  • Thank your provider for submitting the authorization
  • Ask for updates on submission status
  • Share any new symptoms or concerns promptly

Timeline Expectations:

Appeals Process: When to Escalate

Humana Medicare Plans: If your initial request is denied, you have 65 calendar days to file an appeal. The process follows federal Medicare rules:

  1. Redetermination (internal review): 7 days for Part D drugs
  2. Reconsideration by independent review entity: 7 days standard, 72 hours expedited
  3. Administrative Law Judge hearing (if claim value ≥$200)
  4. Medicare Appeals Council review
  5. Federal district court (if claim value ≥$1,730)

Required Documentation for Appeals:

Common Denial Reasons and Solutions

Denial Reason How to Overturn Required Documentation
Insufficient diagnosis documentation Submit detailed staging with objective findings Corneal sensation tests, slit-lamp photos, ICD-10 codes
Inadequate prior treatment trials Document failed conventional therapies Treatment timeline with dates, outcomes, intolerances
Non-formulary status Request formulary exception Medical necessity letter explaining why alternatives won't work
Experimental/investigational Cite FDA approval and established use FDA labeling, peer-reviewed studies, specialty guidelines
From our advocates: We've seen cases where initial denials were overturned simply by adding objective corneal sensation measurements and specific dates of failed lubricant trials. The key is thoroughness—payers want to see that standard care was truly inadequate before approving expensive alternatives.

Pennsylvania-Specific Appeal Rights

Pennsylvania launched its Independent External Review Program in January 2024, offering new rights for commercial (non-Medicare) plan members.

Key Features:

  • 50% success rate in the program's first year—259 out of 517 appeals were overturned
  • 4-month deadline to request external review after receiving your Final Adverse Benefit Determination
  • 45-day decision timeline for standard reviews, 72 hours for expedited
  • Binding decisions—if you win, your insurer must provide coverage immediately

When It Applies:

  • Commercial and marketplace plans (not Medicare Advantage)
  • Medical necessity denials
  • Coverage disputes
  • Experimental treatment denials

How to Access: Visit pa.gov for forms and online submission. The Pennsylvania Insurance Department's Consumer Services office provides free assistance with complex appeals.

For additional support, Counterforce Health's platform can help identify the specific basis for your denial and craft targeted appeals that address payer concerns point-by-point.

FAQ

How long does Humana prior authorization take for Oxervate in Pennsylvania? Standard requests: 72 hours for Medicare Part D, up to 30 days for Medicare Advantage medical benefits. Expedited requests when medically urgent: 24 hours.

What if Oxervate is not on Humana's formulary? Request a formulary exception with your prior authorization. Your doctor must explain why formulary alternatives are not suitable for your condition.

Can I get expedited approval if my condition is worsening? Yes, if your ophthalmologist certifies that standard timeframes could seriously jeopardize your health. Document any signs of corneal thinning or risk of perforation.

Does Pennsylvania's external review apply to Humana Medicare plans? No, Medicare plans follow federal appeals processes. Pennsylvania's external review is only for commercial and marketplace plans.

What manufacturer support is available for Oxervate? Dompé Farmaceutici offers patient assistance programs. Contact their specialty pharmacy or visit their website for current eligibility requirements and application processes.

How do I prove that conventional treatments failed? Your medical records should document specific trials (dates, duration, outcomes) of preservative-free tears, lubricating ointments, bandage contact lenses, and any other treatments attempted before Oxervate.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage and appeals processes. It is not medical advice, legal counsel, or a guarantee of coverage outcomes. Always consult with your healthcare provider about treatment decisions and verify current policy requirements with your insurer. For personalized assistance with Pennsylvania insurance appeals, contact the Pennsylvania Insurance Department or seek help from qualified advocates.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.